依达拉奉对急性脑梗死患者血清Aβ1-40、Aβ1-42水平的影响  

Effects of edaravone on serum beta-amyloids 1-40 and 1-42 in patients with acute cerebral infarction

作　　者：赵连东[1,2] 周永[1,2] 翟其金[1,2] 赵颖[1,2] 张新勇[1,2] 林森[1,2] 徐格林[3] 

机构地区：[1]淮安市第二人民医院 [2]徐州医学院附属淮安医院,江苏淮安223002 [3]南京军区南京总医院神经内科,江苏南京210002

出　　处：《西部医学》2011年第1期101-103,共3页Medical Journal of West China

摘　　要：目的探讨依达拉奉治疗对脑梗死患者血清Aβ(1-40)、Aβ(1-42)的影响。方法选择脑梗死患者64例,将其分为依达拉奉组及对照组,每组32例,依达拉奉组给予静脉滴注依达拉奉30mg/日,每日2次,共治疗14天;对照组不使用依达拉奉,其他治疗相同。两组患者分别于治疗前、治疗后3周、治疗后6周抽取静脉血进行Aβ(1-40)、Aβ(1-42)水平检测,将检测结果进行统计学分析。结果治疗前依达拉奉组血清Aβ(1-40)为1.87±0.39,对照组血清Aβ(1-40)为1.83±0.41,两组间无显著差异(P=0.691)。治疗前依达拉奉组血清Aβ(1-42)为1.43±0.26,对照组血清Aβ(1-42)为1.45±0.29(P=0.675),治疗后3、6W,依达拉奉组Aβ(1-40)水平逐步降低(1.79±0.35 vs 1.34±0.21,P<0.05)。依达拉奉组Aβ(1-42)于治疗后3W升高(1.61±0.32,P<0.05)。对照组Aβ(1-40)和Aβ(1-42)水平无显著改变(P>0.05)。治疗前两组Aβ(1-40)/Aβ(1-42)比率无差异(依达拉奉组1.365,对照组1.314,P=0.582),治疗后3、6W依达拉奉组Aβ(1-40)/Aβ(1-42)比率逐步降低(1.17,0.89),对照组Aβ(1-40)/Aβ(1-42)比率于治疗后3W明显增高(1.58,P=0.048),其后下降,但仍大于治疗前水平。结论依达拉奉可以降低急性脑梗死后血清Aβ(1-40)水平,降低血清Aβ(1-40)/Aβ(1-42)比率。Objective To investigate the effects of edaravone on serum Aβ1-40 and Aβ1-42 in patients with acute cerebral infarction. Methods 64 patients with acute cerebral infarction were enrolled within 48 h of onset. Enrolled patients were randomized into edaravone and control groups. Edaravone was infused at a dose of 30 mg, twice daily for 14 days, and control received similar treatment except edaravone infusion. Results There were no significant difference of serum levels of Aβ1-40 and Aβ1-42 before treatment. Three and six weeks after treatment, the serum levels of Aβ1-40 increased gradually in control group. Aβ1-40 level also increased in edaravone group 3 weeks after treatment also, but the level decreased 6 weeks after treatment. The levels of Aβ1-42 in edaravone group were increased at the point of 3 weeks after treatment, and then begin to decline, but at the point of 6 weeks after treatment, which was higher than that of the baseline. The serum levels of beta-amyloids 1-42 in the control group was decreased significantly 3 weeks after treatment and then increased slightly. The ratio of Aβ1-40/ Aβ1-42 decreased gradually 3 weeks after treatment, but it increased significantly at the time of 3W after treatment. Conclusion Edaravone may decrease serum Aβ1-40 and ratio of Aβ1-40/ Aβ1-42 in patients with acute cerebral infarction.

关 键 词：脑梗死 依达拉奉 血清Aβ1-40/Aβ1-42 

分 类 号：R743.33[医药卫生—神经病学与精神病学]